Related Experiment Videos
Phenytoin in pregnancy: a review of the reported risks
Insights
Antiepileptic drugs, particularly phenytoin, may increase congenital anomalies in infants. This study evaluates the risks of phenytoin during pregnancy against its therapeutic benefits for epilepsy.
Area of Science:
- Neurology
- Teratology
- Pharmacology
Background:
- Studies over 12 years show a near doubling of anomalies in infants exposed to antiepileptic drugs (AEDs) in utero.
- Phenytoin is suspected of causing a congenital syndrome with craniofacial abnormalities, alongside potential carcinogenic and coagulation defects.
Purpose of the Study:
- To investigate the potential role of phenytoin in causing birth defects.
- To evaluate the risks associated with phenytoin use in pregnant epileptic patients.
- To compare the drug's risks with its therapeutic benefits.
Main Methods:
- Review of existing literature on AEDs and congenital anomalies.
- Analysis of reported cases linking phenytoin to specific malformations.
- Consideration of epilepsy severity and necessary AED dosage.
Main Results:
- Phenytoin is strongly implicated in a pattern of congenital malformations.
- Distinguishing individual drug effects in polytherapy is challenging.
- Epilepsy severity influences AED dosage, increasing exposure risks.
Conclusions:
- The use of phenytoin in pregnant epileptic women is questionable due to significant risks.
- Further investigation is needed to balance phenytoin's teratogenic potential against its efficacy in managing epilepsy.
Abstract:
Over the last 12 years several studies have found that the frequency of certain anomalies in children born to mothers treated with antiepileptic drugs during pregnancy has almost doubled. In 1968 Meadow reported certain malformations that suggest a congenital syndrome involving craniofacial abnormalities and that add to the high level of suspicion pointing to phenytoin. Moreover, multi-drug antiepileptics including phenytoin have been reported to induce carcinogenic damage and coagulation defects. In such instances it is always very difficult to distinguish the individual toxic effects of each component. Nevertheless, the possible role of phenytoin in the development of these diseases must be investigated. In addition, the eventual role of the pathologic state itself, epilepsy, cannot be disregarded. Two main aspects must be considered: the disease and its severity which determines the necessity of high dosages of antiepileptic drugs. The administration of phenytoin to pregnant epileptic patients is clearly questionable. Thus the aim of this paper is to evaluate the risks of this drug and compare them with its expected therapeutic benefits.